Sequoia Financial Advisors LLC reduced its position in BioTime, Inc. (NYSEMKT:BTX) by 1.1% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 48,983 shares of the company’s stock after selling 561 shares during the period. Sequoia Financial Advisors LLC’s holdings in BioTime were worth $128,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of BTX. Broadwood Capital Inc. boosted its position in BioTime by 1.4% in the first quarter. Broadwood Capital Inc. now owns 22,164,396 shares of the company’s stock valued at $63,612,000 after buying an additional 300,000 shares during the last quarter. Williams Jones & Associates LLC boosted its position in shares of BioTime by 9.0% in the first quarter. Williams Jones & Associates LLC now owns 60,450 shares of the company’s stock worth $173,000 after buying an additional 5,000 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of BioTime by 0.9% in the first quarter. Geode Capital Management LLC now owns 357,921 shares of the company’s stock worth $1,027,000 after buying an additional 3,101 shares in the last quarter. Finally, State Street Corp boosted its position in shares of BioTime by 5.8% in the first quarter. State Street Corp now owns 787,423 shares of the company’s stock worth $2,259,000 after buying an additional 42,854 shares in the last quarter.
BioTime, Inc. (NYSEMKT:BTX) traded down 1.67% during midday trading on Friday, hitting $3.54. 115,531 shares of the stock traded hands. The stock’s market capitalization is $359.90 million. BioTime, Inc. has a 12-month low of $2.02 and a 12-month high of $4.10. The firm’s 50 day moving average is $3.44 and its 200-day moving average is $3.02.
BioTime (NYSEMKT:BTX) last released its earnings results on Tuesday, August 9th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.43. The firm earned $1.27 million during the quarter, compared to the consensus estimate of $1.75 million. On average, analysts anticipate that BioTime, Inc. will post ($0.22) EPS for the current fiscal year.
A number of brokerages have recently issued reports on BTX. Ladenburg Thalmann began coverage on shares of BioTime in a research note on Friday, September 23rd. They issued a “buy” rating and a $6.00 price objective for the company. Zacks Investment Research cut shares of BioTime from a “buy” rating to a “hold” rating in a research note on Thursday, August 18th.
BioTime Company Profile